Cinclus Pharma Holding
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD). Established in Stockholm, the company is publicly listed on Nasdaq Stockholm and is advancing its drug candidate, linaprazan glurate, through clinical trials. Cinclus Pharma aims to address significant unmet medical needs in acid-related diseases through its specialized drug development efforts.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueDevelopment of new drug candidates for acid-related diseases
Management and execution of clinical trials for drug candidates
Development of strategies for regulatory approval and compliance
Customers
Cinclus Pharma primarily serves healthcare providers and pharmaceutical distributors who require innovative treatments for gastroesophageal reflux disease. The company's drug candidates are aimed at addressing unmet medical needs, making them attractive to hospitals and clinics seeking effective GERD treatments. Additionally, Cinclus Pharma collaborates with research institutions and regulatory bodies to ensure compliance and efficacy of its products. The focus on specialized pharmaceuticals positions the company as a key partner for healthcare systems looking to improve patient outcomes in acid-related diseases.
Purchase GERD treatments for patient care
Distribute innovative drugs to healthcare systems
Collaborate on clinical trials and drug development
Strategy
Cinclus Pharma's strategic priorities include advancing its lead drug candidate, linaprazan glurate, through Phase III clinical trials and securing regulatory approvals. The company is focused on addressing significant unmet medical needs in GERD, which positions it for growth in the pharmaceutical market. Strategic partnerships and collaborations are key to Cinclus Pharma's approach, enabling it to leverage external expertise and resources. The company is also committed to expanding its geographic reach to tap into new markets and increase its competitive advantage.
To bring linaprazan glurate to market
To ensure market entry and compliance
To access new markets and increase revenue
Geography
Cinclus Pharma is headquartered in Stockholm, Sweden, and operates primarily within the European market. The company's strategic location in Sweden allows it to leverage the robust pharmaceutical and healthcare ecosystem in the region. While its primary focus is on the European market, Cinclus Pharma is exploring opportunities for expansion into other regions with significant unmet medical needs for GERD treatments. The company's geographic presence is crucial for accessing key markets and regulatory bodies that facilitate drug approval and distribution.
Risks
Cinclus Pharma faces several risks, including regulatory hurdles that could delay drug approvals and market entry. The company is also exposed to financial risks related to its reliance on equity financing, which may not be sustainable in the long term. Additionally, the competitive landscape in the pharmaceutical industry poses a risk, as larger companies may develop similar treatments. Market acceptance of new drugs is another critical risk, as it depends on the perceived effectiveness and safety of the treatments. Lastly, geopolitical risks, particularly in regions where the company seeks to expand, could impact operations and market access.
- Regulatory Approval DelaysImpact: HighLikelihood: Medium
Could impact market entry and revenue
- Market AcceptanceImpact: HighLikelihood: Low
Depends on perceived effectiveness of new drugs
- Equity Financing RelianceImpact: MediumLikelihood: Medium
May not be sustainable long-term
- Competitive LandscapeImpact: MediumLikelihood: Low
Larger companies may develop similar treatments
Accounting
Judgemental itemsAffects timing of milestone payments
Impacts reported earnings
Affects assets and liabilities
Critical for clinical trial cost management
Similar listed companies
Publicly listed companies with a comparable business focus.
Camurus
CAMX · Health Care
Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Cumberland Pharmaceuticals Inc
CPIX · Pharmaceutical Preparations
EQL Pharma
EQL · Health Care
EQL Pharma is a pharmaceutical company focused on developing and selling generic prescription drugs and medical tests.
Vimian Group
VIMIAN · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Acurx Pharmaceuticals, Inc.
ACXP · Pharmaceutical Preparations
Last updated: 24/09/2026